New Consensus from ACVIM Endorses Diet-First Approach for Canine Enteropathy with Visbiome Vet
The field of veterinary medicine is constantly evolving, and a recent consensus statement from the American College of Veterinary Internal Medicine (ACVIM) has made waves in the industry. The publication offers updated, evidence-based guidance on diagnosing and managing canine chronic inflammatory enteropathy (CIE). ExeGi Pharma LLC, known for its remarkable contributions to digestive health, particularly through its product Visbiome Vet, has welcomed this new guideline as it highlights a diet-first approach in treating affected dogs.
This ACVIM-endorsed statement emphasizes the significance of starting any treatment with dietary trials before considering additional interventions. It introduces the De Simone Formulation (DSF), which consists of a multi-strain probiotic used in Visbiome Vet. This formulation stands out as the only probiotic substantiated by robust randomized clinical trial evidence, thus earning a recommendation for use after dietary trials in cases where initial dietary adjustments fail.
Mark Tewey, the CEO of ExeGi Pharma, expressed his enthusiasm about the ACVIM's decision to publish clear guidance driven by evidence. He noted, "The consensus statement underscores the importance of starting with diet trials and judiciously adding other dietary management options based on clinical improvement." Boasting a decade's worth of scientific investment into Visbiome Vet, the company is proud to be recognized for their commitment to rigorous research and maintaining a high-quality product.
The ACVIM panel's focus on the De Simone Formulation points out its usage in dogs not responding adequately to dietary modifications. This highlights the role of probiotics in treatment regimens for CIE. In their review, the panel indicates that only the DSF probiotic received enough support from clinical trials to earn a conditional recommendation, leaving other probiotic products behind.
Dr. Albert Jergens, DVM, PhD, DACVIM from Iowa State University College of Veterinary Medicine shares in this excitement, noting the consensus not only stresses the dietary management of chronic enteropathy but also suggests the potential of microbiome-directed interventions. He stated, "With Visbiome Vet, clinicians have access to a probiotic supported by randomized clinical trial data, offering an evidence-based option when elimination diets do not suffice." The significance of the panel's recommendation sets a formidable benchmark that many probiotic products have yet to achieve.
Visbiome Vet is fortified with the proprietary De Simone Formulation, delivering billions of viable, lyophilized probiotic bacteria per dose. This ensures that dogs receiving Visbiome Vet get a strong dose of beneficial bacteria aimed at enhancing their gut health. The development of this veterinary probiotic remains grounded in peer-reviewed clinical research, with assurances of strict quality standards overseeing its manufacturing processes to guarantee both potency and purity.
ExeGi Pharma stands at the forefront of innovation in the pet health industry, with a firm foundation rooted in microbiome science. By providing advanced probiotics and biotherapeutic drugs, the company addresses various health concerns in both humans and animals alike. Operating from Rockville, Maryland, ExeGi continues to introduce clinically supported products that aim to enhance health across populations.
In summary, the ACVIM's newly published consensus statement presents a pivotal moment for veterinarians treating canine chronic inflammatory enteropathy, reinforcing the importance of dietary trials and showcasing Visbiome Vet as the leading probiotic backed by rigorous clinical evidence. As veterinarians embrace these new insights into treatment approaches, the hope is not only to improve the quality of life for dogs suffering from CIE but also to promote a greater understanding of the gut's critical role in overall health.
This ACVIM-endorsed statement emphasizes the significance of starting any treatment with dietary trials before considering additional interventions. It introduces the De Simone Formulation (DSF), which consists of a multi-strain probiotic used in Visbiome Vet. This formulation stands out as the only probiotic substantiated by robust randomized clinical trial evidence, thus earning a recommendation for use after dietary trials in cases where initial dietary adjustments fail.
Mark Tewey, the CEO of ExeGi Pharma, expressed his enthusiasm about the ACVIM's decision to publish clear guidance driven by evidence. He noted, "The consensus statement underscores the importance of starting with diet trials and judiciously adding other dietary management options based on clinical improvement." Boasting a decade's worth of scientific investment into Visbiome Vet, the company is proud to be recognized for their commitment to rigorous research and maintaining a high-quality product.
The ACVIM panel's focus on the De Simone Formulation points out its usage in dogs not responding adequately to dietary modifications. This highlights the role of probiotics in treatment regimens for CIE. In their review, the panel indicates that only the DSF probiotic received enough support from clinical trials to earn a conditional recommendation, leaving other probiotic products behind.
Dr. Albert Jergens, DVM, PhD, DACVIM from Iowa State University College of Veterinary Medicine shares in this excitement, noting the consensus not only stresses the dietary management of chronic enteropathy but also suggests the potential of microbiome-directed interventions. He stated, "With Visbiome Vet, clinicians have access to a probiotic supported by randomized clinical trial data, offering an evidence-based option when elimination diets do not suffice." The significance of the panel's recommendation sets a formidable benchmark that many probiotic products have yet to achieve.
Visbiome Vet is fortified with the proprietary De Simone Formulation, delivering billions of viable, lyophilized probiotic bacteria per dose. This ensures that dogs receiving Visbiome Vet get a strong dose of beneficial bacteria aimed at enhancing their gut health. The development of this veterinary probiotic remains grounded in peer-reviewed clinical research, with assurances of strict quality standards overseeing its manufacturing processes to guarantee both potency and purity.
ExeGi Pharma stands at the forefront of innovation in the pet health industry, with a firm foundation rooted in microbiome science. By providing advanced probiotics and biotherapeutic drugs, the company addresses various health concerns in both humans and animals alike. Operating from Rockville, Maryland, ExeGi continues to introduce clinically supported products that aim to enhance health across populations.
In summary, the ACVIM's newly published consensus statement presents a pivotal moment for veterinarians treating canine chronic inflammatory enteropathy, reinforcing the importance of dietary trials and showcasing Visbiome Vet as the leading probiotic backed by rigorous clinical evidence. As veterinarians embrace these new insights into treatment approaches, the hope is not only to improve the quality of life for dogs suffering from CIE but also to promote a greater understanding of the gut's critical role in overall health.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.